372 related articles for article (PubMed ID: 28629170)
1. EGFR and EGFRvIII Promote Angiogenesis and Cell Invasion in Glioblastoma: Combination Therapies for an Effective Treatment.
Keller S; Schmidt MHH
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28629170
[TBL] [Abstract][Full Text] [Related]
2. EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation.
Eskilsson E; Rosland GV; Talasila KM; Knappskog S; Keunen O; Sottoriva A; Foerster S; Solecki G; Taxt T; Jirik R; Fritah S; Harter PN; Välk K; Al Hossain J; Joseph JV; Jahedi R; Saed HS; Piccirillo SG; Spiteri I; Leiss L; Euskirchen P; Graziani G; Daubon T; Lund-Johansen M; Enger PØ; Winkler F; Ritter CA; Niclou SP; Watts C; Bjerkvig R; Miletic H
Neuro Oncol; 2016 Dec; 18(12):1644-1655. PubMed ID: 27286795
[TBL] [Abstract][Full Text] [Related]
3. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
[TBL] [Abstract][Full Text] [Related]
4. The EGFRvIII variant in glioblastoma multiforme.
Gan HK; Kaye AH; Luwor RB
J Clin Neurosci; 2009 Jun; 16(6):748-54. PubMed ID: 19324552
[TBL] [Abstract][Full Text] [Related]
5. The Role of EGFR-Met Interactions in the Pathogenesis of Glioblastoma and Resistance to Treatment.
Guo G; Narayan RN; Horton L; Patel TR; Habib AA
Curr Cancer Drug Targets; 2017; 17(3):297-302. PubMed ID: 28004613
[TBL] [Abstract][Full Text] [Related]
6. The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme.
Chistiakov DA; Chekhonin IV; Chekhonin VP
Eur J Pharmacol; 2017 Sep; 810():70-82. PubMed ID: 28583430
[TBL] [Abstract][Full Text] [Related]
7. EGFRvIII/integrin β3 interaction in hypoxic and vitronectinenriching microenvironment promote GBM progression and metastasis.
Liu Z; Han L; Dong Y; Tan Y; Li Y; Zhao M; Xie H; Ju H; Wang H; Zhao Y; Zheng Q; Wang Q; Su J; Fang C; Fu S; Jiang T; Liu J; Li X; Kang C; Ren H
Oncotarget; 2016 Jan; 7(4):4680-94. PubMed ID: 26717039
[TBL] [Abstract][Full Text] [Related]
8. F25P preproinsulin abrogates the secretion of pro-growth factors from EGFRvIII cells and suppresses tumor growth in an EGFRvIII/wt heterogenic model.
Wei JW; Cui JQ; Zhou X; Fang C; Tan YL; Chen LY; Yang C; Liu M; Kang CS
Cancer Lett; 2016 Sep; 380(1):1-9. PubMed ID: 27317648
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies.
An Z; Aksoy O; Zheng T; Fan QW; Weiss WA
Oncogene; 2018 Mar; 37(12):1561-1575. PubMed ID: 29321659
[TBL] [Abstract][Full Text] [Related]
10. In situ analysis of mutant EGFRs prevalent in glioblastoma multiforme reveals aberrant dimerization, activation, and differential response to anti-EGFR targeted therapy.
Gajadhar AS; Bogdanovic E; Muñoz DM; Guha A
Mol Cancer Res; 2012 Mar; 10(3):428-40. PubMed ID: 22232519
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of tumor development and anti-angiogenic therapy in glioblastoma multiforme.
Onishi M; Kurozumi K; Ichikawa T; Date I
Neurol Med Chir (Tokyo); 2013; 53(11):755-63. PubMed ID: 24162241
[TBL] [Abstract][Full Text] [Related]
12. Targeting EGFRvIII for glioblastoma multiforme.
Yang J; Yan J; Liu B
Cancer Lett; 2017 Sep; 403():224-230. PubMed ID: 28649003
[TBL] [Abstract][Full Text] [Related]
13. Maintenance of EGFR and EGFRvIII expressions in an in vivo and in vitro model of human glioblastoma multiforme.
Stockhausen MT; Broholm H; Villingshøj M; Kirchhoff M; Gerdes T; Kristoffersen K; Kosteljanetz M; Spang-Thomsen M; Poulsen HS
Exp Cell Res; 2011 Jul; 317(11):1513-26. PubMed ID: 21514294
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor variant III-induced glioma invasion is mediated through myristoylated alanine-rich protein kinase C substrate overexpression.
Micallef J; Taccone M; Mukherjee J; Croul S; Busby J; Moran MF; Guha A
Cancer Res; 2009 Oct; 69(19):7548-56. PubMed ID: 19773446
[TBL] [Abstract][Full Text] [Related]
15. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype.
Choe G; Park JK; Jouben-Steele L; Kremen TJ; Liau LM; Vinters HV; Cloughesy TF; Mischel PS
Clin Cancer Res; 2002 Sep; 8(9):2894-901. PubMed ID: 12231534
[TBL] [Abstract][Full Text] [Related]
16. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.
Ramnarain DB; Park S; Lee DY; Hatanpaa KJ; Scoggin SO; Otu H; Libermann TA; Raisanen JM; Ashfaq R; Wong ET; Wu J; Elliott R; Habib AA
Cancer Res; 2006 Jan; 66(2):867-74. PubMed ID: 16424019
[TBL] [Abstract][Full Text] [Related]
17. GBM heterogeneity as a function of variable epidermal growth factor receptor variant III activity.
Lindberg OR; McKinney A; Engler JR; Koshkakaryan G; Gong H; Robinson AE; Ewald AJ; Huillard E; David James C; Molinaro AM; Shieh JT; Phillips JJ
Oncotarget; 2016 Nov; 7(48):79101-79116. PubMed ID: 27738329
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M
Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592
[TBL] [Abstract][Full Text] [Related]
19. The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered.
Gan HK; Cvrljevic AN; Johns TG
FEBS J; 2013 Nov; 280(21):5350-70. PubMed ID: 23777544
[TBL] [Abstract][Full Text] [Related]
20. Identification of an EGFRvIII-JNK2-HGF/c-Met-Signaling Axis Required for Intercellular Crosstalk and Glioblastoma Multiforme Cell Invasion.
Saunders VC; Lafitte M; Adrados I; Quereda V; Feurstein D; Ling Y; Fallahi M; Rosenberg LH; Duckett DR
Mol Pharmacol; 2015 Dec; 88(6):962-9. PubMed ID: 26452771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
